Member Info for sharehunter3

buyers picking up shares now

also at different times yesterday mms looked to be low on available shares with no buy quotes available for times ,
especially in last hour . then its a matter of keeping trying and likely then to get buy quote

think likely test £4 today ,then likely with the number of sellers then be tested and might drop back depending on buying pressure

almost a level finish ,got distracted with the buying last hour at ncyt , hoping for a strong day here tomorrow

had hoped for a move back up again before end of trading ,hoping tomorrow might be a blue day , had planned to look back in around last hour of trading ,stayed watching ncyt with the number of buyers loading up there

planned to look back in before end of trading, was watching ncyt with so much buying starting around last hour over there ,
hoping for a better day here tomorrow

the buyers in France so lucky with their timing again today , buying in before another rise

if rns is released early midmorning tomorrow , be good then to see how share price moves
mms look to running low with shares

WITH NT TO BUY showing so much not easy for people to get the shares they want before end of trading

N T to buy as people try and get shares before end of trading , if rns in morning

if sales update now or morning ,niot going to be easy to get shares if Nt still being quoted

NT FOR BUYING , looks like mms limited shares available

N T TO BUY mms running low on shares

which piece of news are investors watching for

on the move up again ,some liked the opportunity to pick up lower priced shares

moving back up , some were likely thinking dip was an opportunity to buy at that price

bit of a dip ,some might see this as an opportunity

still hoping for a move up again ,when sellers finished taking profits ,other people who not bought in yet wh o read yesterdays rns ,might be seeing redx as an share to buy

The randomised clinical trial, recruiting up to 2,000 residents in 50 care homes across east London, is being led by Professor Jo Martin, President of the Royal College of Pathologists and Professor of Pathology at Queen Mary University of London. The study is using a mobile or near-patient testing (NPT) system for COVID-19 developed by Novacyt (further detail below), which comprises the Company's COVID-19 polymerase chain reaction (PCR) test, direct-to-PCR RNA extraction kit (exsig™ Direct), and portable testing instruments (Q16 and Q32 instruments), to ensure reliable results are received within an hour of testing.

how helpful would this be in US , as well ncyt global sales to around 130 countries

they now moved buy quote up more again